Kuehne + Nagel have helped Sinovac Biotech Ltd., a biopharmaceutical company in China fulfil its first Covid-19 vaccine shipment from Beijing, China to the Dominican Republic.
Sinovac is one of the global players in Covid-19 vaccine research and development. To date, the vaccine has been approved for emergency use or conditional marketing authorisation in more than 20 countries, including China, Brazil, Indonesia, Turkey, and Chile.
The pilot shipment containing 768,000 vials of the vaccine was stored in active temperature-controlled containers and arrived in Santo Domingo, the capital of the Dominican Republic, on February 23.
Siewloong Wong, President of Kuehne + Nagel Asia Pacific said: “We couldn’t be prouder to have started shipments of Sinovac Covid-19 vaccine. At Kuehne + Nagel, we leverage our global pharma & healthcare network and expertise to bring the Sinovac vaccine to the market. We truly appreciate the trust that Sinovac has bestowed upon us.”
Before this shipment, Kuehne + Nagel fulfilled multiple assignments for Sinovac, including an air charter from Beijing to Turkey for door-to-door delivery of nearly 25,000 flu vaccines. Kuehne + Nagel also helped with the shipment of Hepatitis A vaccine to Guatemala, South America as well as making nucleic acid detection kits available to people in Indonesia.
Source: Kuehne + Nagel
